Researchers Achieve a Significant Advancement in Early Diagnosis of Bipolar Disorder in Adolescents

In a groundbreaking studyopens in new tab/window in Biological Psychiatryopens in new tab/window, published by Elsevier, researchers report significant strides in enhancing early diagnosis of bipolar disorder in adolescents. They demonstrate the efficacy of integrating multimodal MRI with behavioral assessments for greater diagnostic precision. Bipolar disorder is a severe neuropsychiatric condition that often emerges during adolescence and is characterized by extreme mood swings.

This research, led by Kangguang Lin, MD, PhD, Department of Affective Disorders, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Medical University, and Jie Wang, PhD, Songjiang Research Institute, Songjiang Hospital, Shanghai Jiao Tong University School of Medicine, could change how we identify young people at risk for bipolar disorder. They aimed to improve the early detection and treatment of this condition, which is crucial for helping young patients in over time.

Dr. Wang explains, “The integration of behavioral and neuroimaging data has the potential to transform the field of neuropsychiatric diagnosis, particularly for conditions like bipolar disorder where early detection is crucial. This approach could lead to earlier interventions, potentially improving outcomes for affected individuals.”

The team used advanced brain imaging techniques to study adolescents who are at risk for bipolar disorder. A group of 309 subjects, including bipolar disorder patients, offspring of bipolar disorder patients (with and without subthreshold symptoms), non-bipolar disorder offspring with subthreshold symptoms, and healthy controls, was analyzed. Behavioral attributes were integrated with multimodal MRI features. Three diagnostic models were developed: a clinical diagnosis model based on behavioral attributes, an MRI-based model, and a comprehensive model integrating both datasets.

Their key finding was that combining various neuroimaging modalities can reveal specific changes in brain networks that signal early-stage bipolar disorder. This approach not only helps diagnose the disorder more accurately, but also offers valuable insights into its biological causes, potentially leading to better and more personalized treatments.

Dr. Lin notes, “Given the challenges in diagnosing bipolar disorder in adolescents, our findings mark a major advance in early detection. By combining various imaging techniques, we can now identify at-risk young people with remarkable accuracy.”

Commenting on the significance of the study, John Krystal, MD, Editor of Biological Psychiatry, says, “We have long expected that brain imaging would help to improve the psychiatric diagnostic process. Here we have a very promising example where the information gained from several forms of MRI, combined with clinical information, improve upon the accuracy of traditional clinical diagnosis.”

Dr. Krystal continues, “When people think about MRI, they often imagine that a radiologist is looking for gross abnormalities that might be easily visible when the MRI is presented on a screen. However, in this case, very detailed automated MRI analyses are conducted that might pick up structural differences that might not be apparent otherwise. Further, this study employed two other forms of MRI imaging, resting state functional MRI (rsFMRI) and diffusion tensor imaging (DTI). rsFMRI analyzes the pattern of communication between brain regions, i.e., their correlated activity. DTI measures the structural integrity of neural pathways by measuring the movement of water within and around the neural pathways in the brain.”

These findings encourage further exploration into advanced imaging in psychiatry, with implications for improving patient outcomes.

Notes for editors

The article is "Enhancing Early Diagnosis of Bipolar Disorder in Adolescents through Multimodal Neuroimaging,” by Jinfeng Wu, PhD, Kangguang Lin, MD, PhD, Weicong Lu, MD, Wenjin Zou, MD, Xiaoyue Li, MD, Yarong Tan, MD, Jingyu Yang, PhD, Danhao Zheng, PhD, Xiaodong Liu, PhD, Bess Yin-Hung Lam, PhD, Guiyun Xu, MD, Kun Wang, Roger S. McIntyre, MD, Fei Wang, PhD, Kwok-Fai So, PhD, and Jie Wang, PhD (https://doi.org/10.1016/j.biopsych.2024.07.018opens in new tab/window). It appears online in Biological Psychiatry, published by Elsevier.

The article is openly available for 30 days at https://www.biologicalpsychiatryjournal.com/article/S0006-3223(24)01485-9/fulltextopens in new tab/window.

Copies of this paper and additional information are also available to credentialed journalists upon request; please contact Rhiannon Bugno at [email protected]opens in new tab/window. Journalists wishing to interview the authors should contact Kangguang Lin, MD, PhD, at:+86 135 6036 0144, [email protected]opens in new tab/window, or Jie Wang, PhD, at +86 18627952376 [email protected]opens in new tab/window.

This project was supported by grants from the National Natural Science Foundation of China and the Science and Technology Program of Guangzhou, China. The authors also acknowledge the contributions of all team members and external collaborators.

The authors’ affiliations and disclosures of financial and conflicts of interests are available in the article.

John H. Krystal, MD, is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available hereopens in new tab/window.

About Biological Psychiatry

Biological Psychiatryopens in new tab/window is the official journal of the Society of Biological Psychiatryopens in new tab/window, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms, and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.

The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.

Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 6th^th out of 279 Psychiatry titles and 15^th out of 309 Neurosciences titles in Journal Citation Reports^TM published by Clarivate. The 2023 Impact Factor score for Biological Psychiatry is 9.6.www.sobp.org/journalopens in new tab/window

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 www.elsevier.com에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.